Foundational guide
FOXO4-DRI Benefits: Every Result Is a Mouse or a Dish
Each benefit attributed to this peptide traces to a real published experiment. None of those experiments involved a human being. Graded by organism, the evidence table has a column that never gets filled in.
The FOXO4-DRI benefits circulating online are not fabricated. Each one traces to a real, published, peer-reviewed experiment, which is more than can be said for most compounds sold through research-supply channels. What is routinely dropped in the retelling is the organism, and that single omission does nearly all of the misleading.
Graded properly, the evidence table below has a column for organism and a column for evidence tier. Across nine years and a dozen studies, no row reaches the tier this site reserves for human trial evidence, because no such trial has ever been registered.
Supplier publishing lot-level data
FOXO4-DRI, Ascension Peptides
Two independent laboratories have certified this product, though on different batches. The code below halves the listed price on the vial.
The two published certificates cover different lots and disagree on fill: Kovera Labs assays batch 55-05260628 at 11.41 mg, MZ Biolabs assays lot 55-01260229 at 8.30 mg, both against a 10 mg label, moving the real figure between $5.87/mg and $8.07/mg. Endotoxin and sterility screens appear on the Kovera lot only, so testing scope here is a batch property rather than a product feature. The vendor spells the product FOX04 with a zero, including in the link.
- Kovera Labs and MZ Biolabs certificates, different lots
- Carriage free above $250
- Same-day dispatch before 2pm CST
Laboratory research material only, not for human consumption. FOXO4-DRI holds no marketing authorisation in any market and has never been administered in a registered human trial. Affiliate links: we may earn a commission at no additional cost to you. Figures checked September 2, 2026.
FOXO4-DRI benefits, graded by organism and tier
Read the organism column before the claim column. It determines how much weight any row can carry, and it is the column that marketing copy omits.
| Claim | What was measured | Organism | Tier |
|---|---|---|---|
| Clears senescent cells | Selective apoptosis via disruption of the FOXO4 and p53 interaction | Mouse, and cells in culture | Preclinical, well replicated |
| Restores physical fitness | Performance in aged and fast-ageing animals | Mouse | Preclinical, single study |
| Restores fur density | Coat regrowth, photographed | Mouse | Preclinical, single study |
| Improves renal function | Markers of kidney function in aged animals | Mouse | Preclinical, single study |
| Protects against chemotoxicity | Neutralised doxorubicin-induced damage | Mouse | Preclinical, model-specific |
| Raises testosterone | Senescent Leydig cell clearance in aged animals | Mouse | Preclinical, single study |
| Improves spermatogenesis | Reduced senescence-associated secretion | Mouse | Preclinical, single study |
| Rejuvenates cartilage cells | Senescent cell removal during expansion | Human chondrocytes, in vitro | Preclinical, in vitro only |
| Builds or preserves muscle | Nothing. No study has used a muscle endpoint | None | No evidence |
| Extends human healthspan | Nothing. No human study exists | None | No evidence |
The two bottom rows are the reason most readers arrive, and they are the two the evidence cannot support at any tier.
What the foundational study established, and what it did not
Nearly every claim on this page originates in a single 2017 paper from the de Keizer group at Erasmus MC, published in Cell. It identified FOXO4 as the protein maintaining senescent-cell viability by binding p53 and preventing apoptosis, then designed a peptide to displace that interaction.
The in vivo results were genuinely striking: reduced doxorubicin toxicity in treated mice, and restored fitness, fur density and renal function in both XpdTTD/TTD fast-ageing mice and naturally aged animals. The mechanism was later refined by a 2025 Nature Communications paper identifying the disordered transactivation domain of p53 as the binding target.
Mechanistic depth is not clinical evidence. Nine years after publication, ClinicalTrials.gov lists no registered interventional study of this peptide in humans. Preclinical results failing to reproduce in people is the ordinary outcome of drug development, and it is the entire reason human trials exist.
The counterweight a benefits page has to carry
Senescent cells are not simply refuse awaiting disposal. Senescence is a tumour-suppressive mechanism: it removes a cell carrying dangerous mutations from the replicative pool. Senescent cells also appear transiently at wound sites and contribute to repair. A compound that eliminates them eliminates those functions alongside the harmful ones.
This is not a hypothetical objection raised for balance. A 2023 study in Circulation reported that eliminating senescent cells could promote the development and progression of pulmonary hypertension. That is an experimental result running directly counter to the general enthusiasm for the approach, and it indicates the effect is context dependent.
Set against an absence of any human safety data, the defensible summary is narrow: an interesting mechanism, a real preclinical result, and a completely uncharacterised human profile. For the analytical side of assessing what is in a vial, see our work on dose accuracy, and for the mechanism-versus-evidence distinction applied elsewhere, the BPC-157 mechanism guide.
Frequently asked questions
- What are the proven benefits of FOXO4-DRI?
- None are proven in humans, because no human trial has been conducted. In mice, the 2017 Cell study reported restored physical fitness, fur density and renal function in aged animals, along with protection against doxorubicin-induced toxicity. Those results have never been reproduced in people.
- Has FOXO4-DRI been tested on human cells?
- Yes, in culture. A 2021 study applied it to human chondrocytes expanded in vitro and reported selective removal of senescent cells. That is human tissue in a dish, which is a different claim from evidence in a living person, and it is frequently misrepresented as the latter.
- Does FOXO4-DRI build or preserve muscle?
- There is no evidence either way, because no study in any species has used a muscle, strength or body-composition endpoint. The compound has no anabolic mechanism and does not act on myostatin or related pathways.
- Are there documented harms from clearing senescent cells?
- Yes. Senescence suppresses tumour formation and contributes to wound healing, so removing those cells removes protective functions too. A 2023 Circulation study found that eliminating senescent cells could promote the development and progression of pulmonary hypertension.
Limitations of the evidence
This guide cannot establish that FOXO4-DRI produces any benefit in a human being. No registered interventional trial of this peptide in humans exists, so there is no clinical efficacy evidence, no human pharmacokinetic data, and no safety profile to weigh benefits against. Every result described here is from a mouse, a rat, or cells in culture, and the failure of preclinical results to reproduce in humans is the ordinary outcome in drug development rather than the exception.
References
Citations are annotated with an evidence tier reflecting study design and replication. See Methodology for criteria.
- 1.Baar MP, Brandt RMC, Putavet DA, et al. · Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging · Cell · 2017PMID 28340339Preclinical
- 2.Bourgeois B, Spreitzer E, Platero-Rochart D, et al. · The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI · Nature Communications · 2025PMID 40593617Preclinical
- 3.Circulation · Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression · Circulation · 2023PMID 36515093Preclinical
- 4.Frontiers in Bioengineering and Biotechnology · Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes · Frontiers in Bioengineering and Biotechnology · 2021PMID 33996787Preclinical
- 5.Aging (Albany NY) · FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice · Aging (Albany NY) · 2020PMID 31959736Preclinical
- 6.Experimental Gerontology · FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion · Experimental Gerontology · 2024PMID 39025385Preclinical